Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Setanaxib by Calliditas Therapeutics for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Setanaxib is under clinical development by Calliditas Therapeutics and currently in Phase II for Primary Biliary Cholangitis (Primary Biliary Cirrhosis)....
Setanaxib by Calliditas Therapeutics for Alport Syndrome: Likelihood of Approval
Setanaxib is under clinical development by Calliditas Therapeutics and currently in Phase II for Alport Syndrome. According to GlobalData, Phase...
Setanaxib by Calliditas Therapeutics for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Setanaxib is under clinical development by Calliditas Therapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Risk adjusted net present value: What is the current valuation of Calliditas Therapeutics's Setanaxib?
Setanaxib is a small molecule commercialized by Calliditas Therapeutics, with a leading Phase II program in Primary Biliary Cholangitis (Primary...
Risk adjusted net present value: What is the current valuation of Calliditas Therapeutics's Setanaxib?
Setanaxib is a small molecule commercialized by Calliditas Therapeutics, with a leading Phase II program in Idiopathic Pulmonary Fibrosis. According...